SAN DIEGO, March 6, 2013 /PRNewswire/ -- HUYA Bioscience International announced today a collaborative partnership with Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co., Ltd. and Shanghai Pharma Engine Co. Ltd. (collectively, "Zhangjiang Biotech Pharmaceutical Base"). HUYA is an international leader in accelerating the global development of China's pharmaceutical innovations. This new partnership will focus on innovations coming out of companies located in Zhangjiang Biotech Pharmaceutical Base that could meet critical global pharmaceutical pipeline needs.
HUYA is one of the first companies to have recognized China's potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to facilitating and promoting the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research institutes throughout China and has pioneered in-licensing both preclinical and clinical stage compounds from the country, utilizing its expertise to advance these compounds for global markets.
Founded in 1996 and supported jointly by the Ministry of Science and Technology, the Ministry of Health, SFDA, Chinese Academy of Sciences and Shanghai Municipal Government, Zhangjiang Biotech Pharmaceutical Base focuses on the development of innovations in biotechnology and pharmaceutical industries. As the core district of Shanghai National Bio-Industry Base with the nickname "Zhangjiang Pharmaceutical Valley", after more than 15 years of development it has attracted more than 300 life science companies, research institutes and related service organizations, both domestic and international, and formed a comprehensive bio-pharmaceutical innovation system and industrial clusters.
The partnership will enable HUYA and Zhangjiang Biotech Pharmaceutical Base to collaborate on promoting new drug development worldwide. Zhangjiang Biotech Pharmaceutical Base will be able to consult with HUYA's team of experts in drug development and globalization. In turn, HUYA will have the first opportunity to evaluate certain research and development projects conducted at Zhangjiang Biotech Pharmaceutical Base and provide support and assistance as needed.
"HUYA is delighted to work with the prestigious Zhangjiang Biotech Pharmaceutical Base in a partnership that aims to advance the global development of innovative pharmaceutical products from China," said Clement Gingras, HUYA's Chief Technical Officer and COO, China. "We are very excited about this partnership and look forward to fruitful collaborations in the years to come."
Senior management of Zhangjiang Biotech Pharmaceutical Base also expressed optimism about this collaboration: "Our goal is to become a top-rank pharmaceutical development base in Asia, and build a world-renowned biomedical innovation platform. We hope that HUYA will help accelerate the global reach of innovations originated from 'Zhangjiang Pharmaceutical Valley' by providing expertise on global pharmaceutical development."
ABOUT HUYA BIOSCIENCE INTERNATIONAL
HUYA is the leader in global pharmaceutical co-development with Chinese partners. With eight offices strategically located across China, the most comprehensive Chinese compound database in the world, and a growing number of collaboration agreements with premier Chinese research and development organizations, HUYA occupies a unique position with regards to the China bio-pharmaceutical industry. Its strategy to identify and license novel Chinese compounds, and to offer Western pharmaceutical companies efficient and comprehensive access to therapeutic innovation in China, means the company can enable efficient global development. HUYA has become a champion in guiding China's biomedical innovations into the worldwide marketplace. HUYA is jointly headquartered in Shanghai and in San Diego, California. More information is available at www.huyabio.com.
ABOUT ZHANGJIANG BIOTECH PHARMACEUTICAL BASE
Since the establishment of State Biotech and Pharmaceutical Industrial Base (Shanghai) in Zhangjiang in 1996 and implementation of the strategic policy of "Focus on Zhangjiang", Zhangjiang Biotech Pharmaceutical Base has gone through tremendous growth and now houses more than 300 institutions and enterprises, including national research institutes, R&D headquarters of multinational pharmaceutical companies, many domestic pharmaceutical companies, CROs, and public service platforms. It has become one of the landmark biopharma park and industrial cluster, known for having the highest density of research and development institutions, the highest capability for innovation and the most prominent result for new drug development in China. More information is available at http://www.zjbpb.com/web/index.asp.
Shanghai Pharma Engine Co., Ltd, a wholly owned subsidiary of Zhangjiang Biotech and Pharmaceutical Base Development Co., is a state-level biopharmaceutical incubator, providing technical, contract research and investment consultation services. More information is available at http://www.zhangjiang.net/tabid/182/ArticleID/462/Default.aspx.
CTO and COO, China
HUYA Bioscience International
SOURCE HUYA Bioscience International